Drug Type RNA aptamer |
Synonyms AON D21, AON-D21 |
Target |
Mechanism C5a inhibitors(complement C5a inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Aptarion Biotech AgStartup |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Community Acquired Pneumonia | Phase 2 | BE | Aptarion Biotech AgStartup | 02 Feb 2024 |
Community Acquired Pneumonia | Phase 2 | FR | Aptarion Biotech AgStartup | 02 Feb 2024 |
Community Acquired Pneumonia | Phase 2 | DE | Aptarion Biotech AgStartup | 02 Feb 2024 |
Community Acquired Pneumonia | Phase 2 | ES | Aptarion Biotech AgStartup | 02 Feb 2024 |
Community Acquired Pneumonia | Phase 2 | GB | Aptarion Biotech AgStartup | 02 Feb 2024 |
Lung Cancer | Phase 1 | DE | Aptarion Biotech AgStartup | 25 Aug 2022 |
Hemoglobinuria, Paroxysmal | Preclinical | US | 07 Dec 2017 | |
Hemoglobinuria, Paroxysmal | Preclinical | DE | Aptarion Biotech AgStartup | 07 Dec 2017 |